The economic evidence is dominated by comparisons of interventions to placebo, with implicit comparisons of different therapies. There is a lack of evaluations of service model innovations to deliver complex packages of care for psoriasis. Primary and secondary integrated clinical and economic research is needed to address the limitations and to identify patient preferences and barriers/facilitators to treatment.
Lis Cordingley, Pauline Nelson, Linda Davies, Darren M. Ashcroft, Christine Bundy, Carolyn Chew‐Graham, Anna Chisholm, Jamie Elvidge, Matthew Hamilton, Rachel Hilton, K. Kane, Chris Keyworth, Alison Littlewood, Karina Lovell, Mark Lunt, Helen McAteer, Dionysios Ntais, Rosa Parisi, Christina J. Pearce, Martin K. Rutter, Deborah Symmons, Helen Young, Christopher Em Griffiths
Don Husereau, Michael Drummond, Federico Augustovski, Esther W. de Bekker‐Grob, Andrew Briggs, Chris Carswell, Lisa Caulley, Nathorn Chaiyakunapruk, Dan Greenberg, Elizabeth Loder, Josephine Mauskopf, C. Daniel Mullins, Stavros Petrou, Raoh‐Fang Pwu, Sophie Staniszewska, Ivett Jakab, Emma Kinloch, Eric Low, Jean Mossman, Declan Noone, Phil Posner, Jo Watson, Wendy Babidge,
.webp)
Discussion(0)
No comments yet. Be the first to comment.